Myxoid liposarcoma

Summary

Myxoid liposarcoma (MONDO:0013280) is a disease with 1 cohort gene and 25 clinical trials. Molecularly, CTAG1B Expression confers sensitivity to Letetresgene Autoleucel in Myxoid Liposarcoma (CIViC Level B); 1 further subtype–drug associations are mapped below. Top therapeutic interventions include atezolizumab, interferon gamma-1b, and nogapendekin alfa inbakicept.

At a glance

• Cohort genes: 1
• Clinical trials: 25
• Precision-medicine evidence (CIViC): 2 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	myxoid liposarcoma
Mondo ID	MONDO:0013280
EFO	EFO:0000613
MeSH	D018208
OMIM	613488
DOID	DOID:5363, DOID:5709
NCIT	C27781
SNOMED CT	404069006
UMLS	C0206634
MedGen	104903
GARD	0015667
Is cancer (heuristic)	no

Also known as: myxoid liposarcoma · myxoid liposarcoma (morphologic abnormality) · myxoid/round cell liposarcoma · Myxoliposarcoma

Data availability: 13 cell lines.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › lipomatous cancer › liposarcoma › myxoid/round cell liposarcoma › myxoid liposarcoma

Related subtypes (1): round cell liposarcoma

Subtypes (1): ovarian myxoid liposarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CTAG1B	HGNC:2491	ENSG00000184033	P78358	Cancer/testis antigen 1	civic_evidence

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CTAG1B	Other/Unknown	no		CTAG/Pcc1

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	1
primordial germ cell in gonad	1
testis	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CTAG1B	36	tissue_specific	marker	primordial germ cell in gonad, male germ line stem cell (sensu Vertebrata) in testis, testis

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CTAG1B	1,470

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
CTAG1B	P78358	23

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
tRNA threonylcarbamoyladenosine metabolic process	1	2808.7×	4e-04	CTAG1B

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Dexamethasone, Pioglitazone, Trabectedin.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CTAG1B	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	CTAG1B

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
CTAG1B	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 25.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	9
PHASE1	9
PHASE1/PHASE2	3
EARLY_PHASE1	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04044768	PHASE2	ACTIVE_NOT_RECRUITING	Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
NCT05120271	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
NCT06843967	PHASE1/PHASE2	RECRUITING	A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
NCT00633165	PHASE2	UNKNOWN	Brostallicin Clinical Trial for Myxoid Liposarcoma
NCT02609984	PHASE2	TERMINATED	Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
NCT02821507	PHASE2	COMPLETED	Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
NCT03063632	PHASE2	COMPLETED	Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
NCT03397186	PHASE2	WITHDRAWN	Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
NCT03651375	PHASE2	UNKNOWN	Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
NCT03816475	PHASE2	UNKNOWN	Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall (LIPO-MYX Trial)
NCT03989596	PHASE2	UNKNOWN	Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
NCT05266196	PHASE1/PHASE2	UNKNOWN	A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
NCT05492682	PHASE1	RECRUITING	START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
NCT06083883	PHASE1	RECRUITING	Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
NCT06414434	PHASE1	ACTIVE_NOT_RECRUITING	BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
NCT06748872	PHASE1	NOT_YET_RECRUITING	EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
NCT02059850	PHASE1	WITHDRAWN	NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
NCT03399448	PHASE1	TERMINATED	NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
NCT03450122	PHASE1	COMPLETED	Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma
NCT03600649	PHASE1	UNKNOWN	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
NCT03670069	PHASE1	TERMINATED	Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
NCT07261657	EARLY_PHASE1	RECRUITING	N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
NCT01957709	EARLY_PHASE1	TERMINATED	Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
NCT04699292	Not specified	RECRUITING	International Prospective Registry on Local Treatment Approaches in MLS
NCT06617572	Not specified	AVAILABLE	Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ATEZOLIZUMAB	4	1
INTERFERON GAMMA-1B	4	1
NOGAPENDEKIN ALFA INBAKICEPT	4	1
TRABECTEDIN	4	1
ITACITINIB	3	1
SECLIDEMSTAT	2	2
BROSTALLICIN	2	1
MIRDAMETINIB	2	1
NY-ESO-1	2	1
BTX-A51	1	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 2 predictive associations from 2 curated evidence items; also 4 diagnostic.

Molecular subtype	Therapy	Effect	Level	CIViC
CTAG1B Expression	Letetresgene Autoleucel	Sensitivity/Response	CIViC B	EID12573
FUS::DDIT3 Fusion	NVP-AEW541	Sensitivity/Response	CIViC D	EID5920